Tomas Uher1, Manuela Vaneckova2, Jan Krasensky2, Lukas Sobisek3, Michaela Tyblova1, Jana Volna1, Zdenek Seidl2, Niels Bergsland4, Michael G Dwyer5, Robert Zivadinov6, Nicola De Stefano7, Maria Pia Sormani8, Eva Kubala Havrdova1, Dana Horakova1. 1. Department of Neurology and Center of Clinical Neuroscience, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic. 2. Department of Radiodiagnostics, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic. 3. Department of Statistics and Probability, University of Economics-Prague, Prague, Czech Republic. 4. Buffalo Neuroimaging Analysis Center, Department of Neurology, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, The State University of New York, Buffalo, NY, USA/IRCCS 'S. Maria Nascente', Don Carlo Gnocchi Foundation, Milan, Italy. 5. Buffalo Neuroimaging Analysis Center, Department of Neurology, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, The State University of New York, Buffalo, NY, USA. 6. Buffalo Neuroimaging Analysis Center, Department of Neurology, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, The State University of New York, Buffalo, NY, USA/Translational Imaging Center, Clinical and Translational Science Institute, University at Buffalo, The State University of New York, Buffalo, NY, USA. 7. Department of Medicine, Surgery and Neuroscience, University of Siena, Siena, Italy. 8. Department of Health Science, University of Genoa, Genoa, Italy.
Abstract
BACKGROUND: Volumetric MRI surrogate markers of disease progression are lacking. OBJECTIVE: To establish cut-off values of brain volume loss able to discriminate between healthy controls and MS patients. METHODS: In total, 386 patients after first demyelinating event suggestive of MS (CIS), 964 relapsing-remitting MS (RRMS) patients, 63 secondary-progressive MS (SPMS) patients and 58 healthy controls were included in this longitudinal study. A total of 11,438 MRI scans performed on the same MRI scanner with the same protocol were analysed. Annualised percentage changes of whole brain, grey matter, thalamus and corpus callosum volumes were estimated. We investigated cut-offs able to discriminate between healthy controls and MS patients. RESULTS: At a predefined specificity of 90%, the annualised percentage change cut-off of corpus callosum volume (-0.57%) was able to distinguish between healthy controls and patients with the highest sensitivity (51% in CIS, 48% in RRMS and 42% in SPMS patients). Lower sensitivities (22%-49%) were found for cut-offs of whole brain, grey matter and thalamic volume loss. Among CIS and RRMS patients, cut-offs were associated with greater accumulation of disability. CONCLUSION: We identified cut-offs of annualised global and regional brain volume loss rates able to discriminate between healthy controls and MS patients.
BACKGROUND: Volumetric MRI surrogate markers of disease progression are lacking. OBJECTIVE: To establish cut-off values of brain volume loss able to discriminate between healthy controls and MSpatients. METHODS: In total, 386 patients after first demyelinating event suggestive of MS (CIS), 964 relapsing-remitting MS (RRMS) patients, 63 secondary-progressive MS (SPMS) patients and 58 healthy controls were included in this longitudinal study. A total of 11,438 MRI scans performed on the same MRI scanner with the same protocol were analysed. Annualised percentage changes of whole brain, grey matter, thalamus and corpus callosum volumes were estimated. We investigated cut-offs able to discriminate between healthy controls and MSpatients. RESULTS: At a predefined specificity of 90%, the annualised percentage change cut-off of corpus callosum volume (-0.57%) was able to distinguish between healthy controls and patients with the highest sensitivity (51% in CIS, 48% in RRMS and 42% in SPMS patients). Lower sensitivities (22%-49%) were found for cut-offs of whole brain, grey matter and thalamic volume loss. Among CIS and RRMS patients, cut-offs were associated with greater accumulation of disability. CONCLUSION: We identified cut-offs of annualised global and regional brain volume loss rates able to discriminate between healthy controls and MSpatients.
Authors: Michael G Dwyer; Jesper Hagemeier; Niels Bergsland; Dana Horakova; Jonathan R Korn; Nasreen Khan; Tomas Uher; Jennie Medin; Diego Silva; Manuela Vaneckova; Eva Kubala Havrdova; Robert Zivadinov Journal: Neuroimage Clin Date: 2018-02-07 Impact factor: 4.881
Authors: Ludwig Rasche; Michael Scheel; Karen Otte; Patrik Althoff; Annemieke B van Vuuren; Rene M Gieß; Joseph Kuchling; Judith Bellmann-Strobl; Klemens Ruprecht; Friedemann Paul; Alexander U Brandt; Tanja Schmitz-Hübsch Journal: Front Neurol Date: 2018-08-29 Impact factor: 4.003
Authors: Tomas Uher; Jan Krasensky; Charles Malpas; Niels Bergsland; Michael G Dwyer; Eva Kubala Havrdova; Manuela Vaneckova; Dana Horakova; Robert Zivadinov; Tomas Kalincik Journal: Neurol Neuroimmunol Neuroinflamm Date: 2021-03-16
Authors: Frederique M Boonstra; Meaghan Clough; Myrte Strik; Anneke van der Walt; Helmut Butzkueven; Owen B White; Meng Law; Joanne Fielding; Scott C Kolbe Journal: Brain Commun Date: 2022-03-17
Authors: Gabriel Bsteh; Harald Hegen; Patrick Altmann; Michael Auer; Klaus Berek; Franziska Di Pauli; Fritz Leutmezer; Paulus Rommer; Sebastian Wurth; Anne Zinganell; Tobias Zrzavy; Florian Deisenhammer; Thomas Berger Journal: Eur J Neurol Date: 2021-04-02 Impact factor: 6.089